Keeping ahead in China means adapting to a shifting market, analysts say

April 1, 2013 by Arezu Sarvestani

Analysts at PricewaterhouseCoopers say that life sciences companies that are ready to evolve along with China's shifting landscape will be in the best position to capitalize on what's projected to become a $1 trillion healthcare market within the decade.

China with flag overlay

Many medical device companies have their eye on China - and with good reason - but the country's approach to healthcare is shifting, and companies that hope to capitalize on the China's exponential growth must be prepared to change with it, according to analysts at PricewaterhouseCoopers.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.